Evidence map›Paper›PMID 41194063›Full record

ArticleBMC veterinary research2025

Recombinant rSF toxoid enhances efficacy of bacterin-inactivated vaccine against F18+ Escherichia coli-induced edema disease in swine.

Yuqing Liu, Huawei Wu, Fanghong Zhang, Xiaolin Yang, Tinghua Huang, Bin Wu, Guoping Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yuqing Liu *College of Life Science, Yangtze University, No.88-2 Jing Mi Road, Jingzhou, 434025, Hu Bei, China.
Huawei Wu *College of Life Science, Yangtze University, No.88-2 Jing Mi Road, Jingzhou, 434025, Hu Bei, China.
Fanghong ZhangCollege of Animal Science, Yangtze University, No.88-2 Jing Mi Road, Jingzhou, 434025, Hu Bei, China.
Xiaolin YangCollege of Animal Science, Yangtze University, No.88-2 Jing Mi Road, Jingzhou, 434025, Hu Bei, China.
Tinghua HuangCollege of Animal Science, Yangtze University, No.88-2 Jing Mi Road, Jingzhou, 434025, Hu Bei, China.
Bin WuThe Cooperative Innovation Center for Sustainable Pig Production, Wuhan, 430070, Hu Bei, China. wub@mail.hzau.edu.cn.
Guoping LiuCollege of Animal Science, Yangtze University, No.88-2 Jing Mi Road, Jingzhou, 434025, Hu Bei, China. guoping.liu@yangtzeu.edu.cn.

Funding

Key R&D Projects in Hubei Province 2023BBB045
6 · The paper itself

Abstract

backgroundEdema disease (ED) and post-weaning diarrhea (PWD) are major health and economic challenges in the swine industry, primarily caused by F18

resultsRecombinant rSF toxoid (fusion of SLT-IIe B subunit and FedF adhesin) mixed with Ee strain formed a novel rSF toxoid bacterin-inactivated vaccine. Compared to conventional bacterin-inactivated vaccine, the rSF vaccine group showed significantly higher protection efficacy against F18+ SLTEC challenge, with reduced histological scores, attenuated inflammation, decreased creatinine levels, and minimized kidney damage, alongside increased average daily gain and nitric oxide levels.

conclusionrSF toxoid addition safely enhances protection efficacy against F18+ SLTEC and alleviates renal pathology.

Indexed as

Edema Disease of SwineEscherichia coli InfectionsEscherichia coli VaccinesShiga-Toxigenic Escherichia coliSwine DiseasesToxoidsAnimalsEscherichia coli ProteinsSwineVaccines, InactivatedVaccines, SyntheticEscherichia coli ProteinsEscherichia coli VaccinesToxoidsVaccines, InactivatedVaccines, SyntheticEdema diseaseF18+ Shiga toxin-producing E. coli (SLTEC)Protection efficacyRSF toxoid

Identifiers

PMID41194063
PMCPMC12590897

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.